Overall, 22.8% of survivors reported problems with task efficiency, 12.4% with memory, 12.7% with organization, and 12.3% emotional regulation (Table 2). Approximately 20% to 30% of survivors who had at least one moderate chronic condition reported impairments in task efficiency and memory. Exploratory analysis revealed that risk of impairment in task efficiency, memory, and emotional regulation was associated with growth hormone deficiency, gonadal dysfunction, and marginally for hypothyroidism (Supplementary Table 3, available online).
| Chronic health condition (grade) . | No. . | Neurocognitive domain . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Task efficiency . | Memory . | Organization . | Emotional regulation . | ||||||
| Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | ||
| All survivors | 5507 | 53.3 (12.9)† | 22.8 | 51.7 (11.9)† | 12.4 | 49.7 (10.1)† | 12.7 | 51.8 (10.8)† | 12.3 |
| Cardiovascular | |||||||||
| None | 4167 | 53.0 (12.8) | 21.8 | 51.3 (11.7) | 12.7 | 49.5 (10.0) | 12.0 | 51.6 (10.8) | 11.8 |
| Mild (1) | 430 | 54.4 (13.5) | 26.0 | 53.0 (12.3) | 15.6 | 50.8 (10.5) | 15.6 | 52.8 (11.1) | 14.9 |
| Moderate (2) | 717 | 53.9 (13.3) | 25.0 | 52.7 (12.2) | 14.2 | 50.1 (10.1) | 14.4 | 52.4 (10.9) | 13.2 |
| Severe/life-threatening (3/4) | 193 | 55.5 (12.4) | 29.0 | 54.0 (12.2) | 19.7 | 51.5 (10.6) | 16.6 | 53.7 (10.3) | 13.0 |
| Endocrine | |||||||||
| None | 4017 | 52.4 (12.3) | 20.7 | 51.0 (11.5) | 11.9 | 49.5 (10.1) | 12.2 | 51.2 (10.7) | 11.1 |
| Mild (1) | 230 | 57.7 (15.3) | 35.2 | 55.5 (13.2) | 22.2 | 51.1 (10.5) | 17.8 | 53.9 (11.2) | 17.4 |
| Moderate (2) | 772 | 56.1 (14.2) | 29.0 | 53.4 (12.6) | 17.1 | 50.2 (9.9) | 12.7 | 53.0 (10.8) | 14.0 |
| Severe/life-threatening (3/4) | 488 | 54.0 (12.9) | 24.4 | 52.8 (12.6) | 15.8 | 50.3 (10.1) | 14.3 | 53.8 (11.1) | 16.8 |
| Pulmonary | |||||||||
| None | 4547 | 52.8 (12.6) | 21.8 | 51.3 (11.6) | 12.4 | 49.4 (10.0) | 11.8 | 51.5 (10.7) | 11.2 |
| Mild (1) | 868 | 55.3 (13.8) | 26.8 | 53.3 (12.7) | 17.6 | 51.1 (10.4) | 16.8 | 53.4 (11.3) | 16.5 |
| Moderate (2) | 32 | 52.9 (9.5) | 18.8 | 53.6 (11.6) | 12.5 | 52.7 (10.1) | 15.6 | 52.0 (11.9) | 15.6 |
| Severe/life-threatening (3/4) | 60 | 60.1 (15.1) | 38.3 | 57.9 (14.8) | 28.3 | 52.4 (9.9) | 18.3 | 57.0 (11.3) | 26.7 |
| Chronic health condition (grade) . | No. . | Neurocognitive domain . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Task efficiency . | Memory . | Organization . | Emotional regulation . | ||||||
| Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | ||
| All survivors | 5507 | 53.3 (12.9)† | 22.8 | 51.7 (11.9)† | 12.4 | 49.7 (10.1)† | 12.7 | 51.8 (10.8)† | 12.3 |
| Cardiovascular | |||||||||
| None | 4167 | 53.0 (12.8) | 21.8 | 51.3 (11.7) | 12.7 | 49.5 (10.0) | 12.0 | 51.6 (10.8) | 11.8 |
| Mild (1) | 430 | 54.4 (13.5) | 26.0 | 53.0 (12.3) | 15.6 | 50.8 (10.5) | 15.6 | 52.8 (11.1) | 14.9 |
| Moderate (2) | 717 | 53.9 (13.3) | 25.0 | 52.7 (12.2) | 14.2 | 50.1 (10.1) | 14.4 | 52.4 (10.9) | 13.2 |
| Severe/life-threatening (3/4) | 193 | 55.5 (12.4) | 29.0 | 54.0 (12.2) | 19.7 | 51.5 (10.6) | 16.6 | 53.7 (10.3) | 13.0 |
| Endocrine | |||||||||
| None | 4017 | 52.4 (12.3) | 20.7 | 51.0 (11.5) | 11.9 | 49.5 (10.1) | 12.2 | 51.2 (10.7) | 11.1 |
| Mild (1) | 230 | 57.7 (15.3) | 35.2 | 55.5 (13.2) | 22.2 | 51.1 (10.5) | 17.8 | 53.9 (11.2) | 17.4 |
| Moderate (2) | 772 | 56.1 (14.2) | 29.0 | 53.4 (12.6) | 17.1 | 50.2 (9.9) | 12.7 | 53.0 (10.8) | 14.0 |
| Severe/life-threatening (3/4) | 488 | 54.0 (12.9) | 24.4 | 52.8 (12.6) | 15.8 | 50.3 (10.1) | 14.3 | 53.8 (11.1) | 16.8 |
| Pulmonary | |||||||||
| None | 4547 | 52.8 (12.6) | 21.8 | 51.3 (11.6) | 12.4 | 49.4 (10.0) | 11.8 | 51.5 (10.7) | 11.2 |
| Mild (1) | 868 | 55.3 (13.8) | 26.8 | 53.3 (12.7) | 17.6 | 51.1 (10.4) | 16.8 | 53.4 (11.3) | 16.5 |
| Moderate (2) | 32 | 52.9 (9.5) | 18.8 | 53.6 (11.6) | 12.5 | 52.7 (10.1) | 15.6 | 52.0 (11.9) | 15.6 |
| Severe/life-threatening (3/4) | 60 | 60.1 (15.1) | 38.3 | 57.9 (14.8) | 28.3 | 52.4 (9.9) | 18.3 | 57.0 (11.3) | 26.7 |
| Chronic health condition (grade) . | No. . | Neurocognitive domain . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Task efficiency . | Memory . | Organization . | Emotional regulation . | ||||||
| Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | ||
| All survivors | 5507 | 53.3 (12.9)† | 22.8 | 51.7 (11.9)† | 12.4 | 49.7 (10.1)† | 12.7 | 51.8 (10.8)† | 12.3 |
| Cardiovascular | |||||||||
| None | 4167 | 53.0 (12.8) | 21.8 | 51.3 (11.7) | 12.7 | 49.5 (10.0) | 12.0 | 51.6 (10.8) | 11.8 |
| Mild (1) | 430 | 54.4 (13.5) | 26.0 | 53.0 (12.3) | 15.6 | 50.8 (10.5) | 15.6 | 52.8 (11.1) | 14.9 |
| Moderate (2) | 717 | 53.9 (13.3) | 25.0 | 52.7 (12.2) | 14.2 | 50.1 (10.1) | 14.4 | 52.4 (10.9) | 13.2 |
| Severe/life-threatening (3/4) | 193 | 55.5 (12.4) | 29.0 | 54.0 (12.2) | 19.7 | 51.5 (10.6) | 16.6 | 53.7 (10.3) | 13.0 |
| Endocrine | |||||||||
| None | 4017 | 52.4 (12.3) | 20.7 | 51.0 (11.5) | 11.9 | 49.5 (10.1) | 12.2 | 51.2 (10.7) | 11.1 |
| Mild (1) | 230 | 57.7 (15.3) | 35.2 | 55.5 (13.2) | 22.2 | 51.1 (10.5) | 17.8 | 53.9 (11.2) | 17.4 |
| Moderate (2) | 772 | 56.1 (14.2) | 29.0 | 53.4 (12.6) | 17.1 | 50.2 (9.9) | 12.7 | 53.0 (10.8) | 14.0 |
| Severe/life-threatening (3/4) | 488 | 54.0 (12.9) | 24.4 | 52.8 (12.6) | 15.8 | 50.3 (10.1) | 14.3 | 53.8 (11.1) | 16.8 |
| Pulmonary | |||||||||
| None | 4547 | 52.8 (12.6) | 21.8 | 51.3 (11.6) | 12.4 | 49.4 (10.0) | 11.8 | 51.5 (10.7) | 11.2 |
| Mild (1) | 868 | 55.3 (13.8) | 26.8 | 53.3 (12.7) | 17.6 | 51.1 (10.4) | 16.8 | 53.4 (11.3) | 16.5 |
| Moderate (2) | 32 | 52.9 (9.5) | 18.8 | 53.6 (11.6) | 12.5 | 52.7 (10.1) | 15.6 | 52.0 (11.9) | 15.6 |
| Severe/life-threatening (3/4) | 60 | 60.1 (15.1) | 38.3 | 57.9 (14.8) | 28.3 | 52.4 (9.9) | 18.3 | 57.0 (11.3) | 26.7 |
| Chronic health condition (grade) . | No. . | Neurocognitive domain . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Task efficiency . | Memory . | Organization . | Emotional regulation . | ||||||
| Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | Mean (SD) . | % impaired* . | ||
| All survivors | 5507 | 53.3 (12.9)† | 22.8 | 51.7 (11.9)† | 12.4 | 49.7 (10.1)† | 12.7 | 51.8 (10.8)† | 12.3 |
| Cardiovascular | |||||||||
| None | 4167 | 53.0 (12.8) | 21.8 | 51.3 (11.7) | 12.7 | 49.5 (10.0) | 12.0 | 51.6 (10.8) | 11.8 |
| Mild (1) | 430 | 54.4 (13.5) | 26.0 | 53.0 (12.3) | 15.6 | 50.8 (10.5) | 15.6 | 52.8 (11.1) | 14.9 |
| Moderate (2) | 717 | 53.9 (13.3) | 25.0 | 52.7 (12.2) | 14.2 | 50.1 (10.1) | 14.4 | 52.4 (10.9) | 13.2 |
| Severe/life-threatening (3/4) | 193 | 55.5 (12.4) | 29.0 | 54.0 (12.2) | 19.7 | 51.5 (10.6) | 16.6 | 53.7 (10.3) | 13.0 |
| Endocrine | |||||||||
| None | 4017 | 52.4 (12.3) | 20.7 | 51.0 (11.5) | 11.9 | 49.5 (10.1) | 12.2 | 51.2 (10.7) | 11.1 |
| Mild (1) | 230 | 57.7 (15.3) | 35.2 | 55.5 (13.2) | 22.2 | 51.1 (10.5) | 17.8 | 53.9 (11.2) | 17.4 |
| Moderate (2) | 772 | 56.1 (14.2) | 29.0 | 53.4 (12.6) | 17.1 | 50.2 (9.9) | 12.7 | 53.0 (10.8) | 14.0 |
| Severe/life-threatening (3/4) | 488 | 54.0 (12.9) | 24.4 | 52.8 (12.6) | 15.8 | 50.3 (10.1) | 14.3 | 53.8 (11.1) | 16.8 |
| Pulmonary | |||||||||
| None | 4547 | 52.8 (12.6) | 21.8 | 51.3 (11.6) | 12.4 | 49.4 (10.0) | 11.8 | 51.5 (10.7) | 11.2 |
| Mild (1) | 868 | 55.3 (13.8) | 26.8 | 53.3 (12.7) | 17.6 | 51.1 (10.4) | 16.8 | 53.4 (11.3) | 16.5 |
| Moderate (2) | 32 | 52.9 (9.5) | 18.8 | 53.6 (11.6) | 12.5 | 52.7 (10.1) | 15.6 | 52.0 (11.9) | 15.6 |
| Severe/life-threatening (3/4) | 60 | 60.1 (15.1) | 38.3 | 57.9 (14.8) | 28.3 | 52.4 (9.9) | 18.3 | 57.0 (11.3) | 26.7 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
